ArticleAnnals of hematology2025
Prognostic impact of GNRI-IPI score in octogenarians with diffuse large B-Cell lymphoma treated with R-CHOP.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) outcomes decline in patients aged ≥ 80 years, with R-CHOP as standard therapy despite frequent dose reductions due to frailty. This study evaluates treatment outcomes and prognostic factors, including the Geriatric Nutritional Risk Index (GNRI), in this population. We retrospectively analyzed 102 patients aged ≥ 80 years with newly diagnosed DLBCL treated with full-dose or dose-attenuated R-CHOP at Seoul National University Bundang Hospital (2005-2024). Baseline characteristics, treatment delivery, toxicities, and survival were assessed using Kaplan-Meier methods and Cox proportional hazards models. Median age was 83 years; 57.8% had advanced-stage disease, and 55.8% were high/high-intermediate IPI risk. Median relative dose intensity was 54.0%; 65.7% completed treatment. Grade 3-4 toxicities occurred in 33.3%. At 2 years, overall survival (OS) was 71.8% and progression-free survival (PFS) was 67.2%. In multivariate analysis, low GNRI (< 81.6) independently predicted worse OS (HR 3.09, 95% CI 1.40-6.82, p = 0.005) and PFS (HR 2.84, 95% CI 1.34-6.02, p = 0.006); IPI ≥ 3 was associated with inferior PFS (HR 2.11, 95% CI 1.03-4.32, p = 0.042). The composite GNRI-IPI score stratified OS and PFS effectively, with high-risk showing worse survival (OS: HR 6.44, 95% CI 2.45-16.93, p < 0.001; PFS: HR 6.00, 95% CI 2.42-14.92, p < 0.001) and higher grade 3-4 toxicities (63.6% vs. 22.0% in low-risk, p = 0.023). GNRI-IPI enhances risk stratification and toxicity prediction in very elderly DLBCL patients, supporting nutritional integration in prognostication. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.